Integrity Alliance LLC. Has $2.63 Million Stock Position in Amgen Inc. $AMGN

Key Points

• Integrity Alliance LLC increased its stake in Amgen Inc. by 66.2% during the first quarter, totaling $2.63 million with 8,436 shares owned.
• Amgen reported $6.02 EPS for the last quarter, exceeding expectations of $5.28, along with a revenue of $9.18 billion which also surpassed analyst forecasts.
• The company announced a quarterly dividend of $2.38 per share, resulting in an annualized dividend yield of 3.4% for its shareholders.

Integrity Alliance LLC. increased its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 66.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,436 shares of the medical research company's stock after buying an additional 3,359 shares during the period. Integrity Alliance LLC.'s holdings in Amgen were worth $2,628,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Wealth Preservation Advisors LLC bought a new stake in shares of Amgen during the first quarter valued at approximately $25,000. Pinney & Scofield Inc. bought a new stake in Amgen during the 4th quarter valued at $26,000. First Pacific Financial raised its holdings in Amgen by 304.5% during the first quarter. First Pacific Financial now owns 89 shares of the medical research company's stock worth $28,000 after buying an additional 67 shares during the last quarter. Activest Wealth Management lifted its stake in shares of Amgen by 3,433.3% in the first quarter. Activest Wealth Management now owns 106 shares of the medical research company's stock valued at $33,000 after buying an additional 103 shares in the last quarter. Finally, Heck Capital Advisors LLC bought a new position in shares of Amgen in the fourth quarter valued at $36,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Down 0.5%

AMGN stock opened at $278.51 on Thursday. The stock has a market cap of $149.94 billion, a P/E ratio of 22.77, a P/E/G ratio of 2.43 and a beta of 0.49. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. The stock's fifty day simple moving average is $293.29 and its two-hundred day simple moving average is $292.22. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $339.17.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, topping analysts' consensus estimates of $5.28 by $0.74. The company had revenue of $9.18 billion for the quarter, compared to analysts' expectations of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The business's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the business posted $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date is Friday, August 22nd. Amgen's payout ratio is presently 77.84%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Raymond James Financial initiated coverage on shares of Amgen in a report on Wednesday, September 3rd. They issued a "market perform" rating on the stock. Bank of America increased their price objective on Amgen from $252.00 to $261.00 and gave the stock an "underperform" rating in a research note on Wednesday, July 23rd. Morgan Stanley lifted their target price on Amgen from $330.00 to $333.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Cantor Fitzgerald reissued a "neutral" rating and issued a $305.00 price target on shares of Amgen in a research report on Tuesday, June 24th. Finally, William Blair reaffirmed an "outperform" rating on shares of Amgen in a report on Tuesday, June 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Amgen currently has a consensus rating of "Hold" and an average price target of $304.43.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the business's stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president directly owned 7,209 shares in the company, valued at $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.76% of the stock is currently owned by insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.